Loading Bonafide Research

Australia Cardiovascular Devices Market Overview, 2031

The Australia Cardiovascular Devices Market is anticipated to grow at more than 9.50% CAGR from 2026 to 2031.

Key Insights


• According to the research report, "Australia Cardiovascular Devices Market Outlook, 2031," published by Bonafide Research, the Australia Cardiovascular Devices Market is anticipated to grow at more than 9.50% CAGR from 2026 to 2031.
• Australia’s cardiovascular device market is defined by rapid clinical adoption of minimally invasive transcatheter structural heart interventions, supported by favorable public reimbursement frameworks under the Medicare Benefits Schedule (MBS). Procedural TAVI (Transcatheter Aortic Valve Implantation) volume in Australia has surpassed traditional surgical aortic valve replacement (SAVR), driven by expanded MBS coverage for low- and intermediate-risk patients managed by multidisciplinary Heart Teams. A major technological breakthrough includes clinical advancements and national deployment of leadless dual-chamber pacemakers, extravascular implantable cardioverter-defibrillators (EV-ICDs), and advanced intravascular lithotripsy (IVL) systems, which enable interventional cardiologists to treat severely calcified coronary lesions without major surgical trauma.
• Clinicians routinely deploy long-wear continuous ECG patch monitors, smart implantable loop recorders (ILRs), and AI-driven remote monitoring algorithms to screen for silent atrial fibrillation and manage chronic heart failure. By leveraging cloud-based platforms, regional health districts in outer-metropolitan and rural Australia can perform automated remote risk triage, curbing unnecessary patient travel costs and reducing acute emergency hospital readmissions across state public health systems.
• Strict regulatory oversight enforced by the Therapeutic Goods Administration (TGA) ensures high clinical evidence standards, but ongoing regulatory reforms present compliance hurdles for device manufacturers. The TGA’s reclassification of active implantable and high-risk Class III cardiovascular devices alongside extended compliance transition pathways requires continuous clinical trial data generation, post-market surveillance (PMS), and Australian Register of Therapeutic Goods (ARTG) updates. Additionally, price containment pressure from the federal Prostheses List (PL) reform compresses reimbursement margins on mature surgical hardware, prompting suppliers to focus commercial efforts on high-value, novel interventional platforms.

Market Outlook


• The market outlook point highlights the ongoing decentralization of cardiac diagnostic pathways and low-complexity electrophysiology procedures toward outpatient day-surgery clinics, private ambulatory facilities, and community-based health networks. Supported by federal health strategies aimed at easing bed capacity pressures in major metropolitan tertiary public hospitals, state health departments are directing capital toward expanding ambulatory interventional suites. Medical device vendors providing single-use, highly portable diagnostic hardware paired with cloud-based remote patient monitoring tools will gain preferred procurement standing across public hospital networks and growing private health operators like Ramsay Health Care and Healthscope.
• Crucial trade associations and professional clinical bodies such as the Medical Technology Association of Australia (MTAA), the Cardiac Society of Australia and New Zealand (CSANZ), and the Australian & New Zealand Society of Cardiac & Thoracic Surgeons (ANZSCTS) continue to shape practice guidelines, accreditation standards, and national reimbursement policies, while leading international and domestic medical technology companies including Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, BIOTRONIK, GE Healthcare, Siemens Healthineers, Terumo Corporation, and CathRx drive ongoing commercial and clinical deployment across Australia.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


Market Dynamics


Driver: Medicare benefits schedule expansion, age-related structural heart burden, and federal health funding
The primary catalyst fueling the Australian cardiovascular devices market is the severe national burden of cardiovascular diseases costing the Australian healthcare system nearly $17 billion annually coupled with proactive public funding via the Medicare Benefits Schedule (MBS). With a rapidly aging demographic and high rates of chronic risk factors such as hypertension, coronary artery disease, and structural heart degeneration, clinical demand for minimally invasive interventions continues to grow.
Challenge: Prostheses list pricing compression, TGA reclassification, and UDI mandates
A major commercial challenge for medical technology providers in Australia is navigating structural reimbursement reforms alongside increasingly stringent regulatory compliance obligations. Under the federal Prescribed List (formerly Prostheses List) reforms, the Australian Government has implemented staged benefit reductions to align private health insurance reimbursement rates closer to public hospital purchasing prices.
Trend: Expansion of virtual care infrastructure, AI arrhythmia telemetry, and leadless cardiac technologies
A dominant structural trend defining the Australian cardiovascular landscape is the rapid virtualization of chronic cardiac care and the clinical shift toward leadless, minimally disruptive implantable devices. To overcome geographical access barriers across outer-metropolitan, regional, and remote Australia, state health departments and cardiologists are embedding cloud-connected remote patient monitoring (RPM) directly into chronic disease care pathways. Advanced diagnostic tools such as long-wear wearable patch ECGs, smart implantable loop recorders (ILRs), and leadless pacemakers are routinely integrated with artificial intelligence algorithms.

Segment Analysis



Australia Cardiovascular Devices By Device Type
• Australia’s therapeutic and surgical cardiovascular-device segment is shaped by risk-based TGA regulation, strong post-market oversight, and increasing integration of diagnostic functions into therapeutic devices. The segment includes pacemakers, ICDs, CRT systems, prosthetic heart valves, coronary intervention devices, electrophysiology systems, and other implantable technologies. A distinctive feature of the Australian framework is that a therapeutic device can receive a higher-risk classification when its embedded diagnostic function significantly determines patient management for example, automated defibrillators and closed-loop systems. This encourages manufacturers to treat sensing, decision-making, and therapy delivery as an integrated device proposition rather than separate functions.
• Australia’s diagnostic and monitoring segment is increasingly moving toward connected, wearable, software-enabled, and continuous physiological monitoring. ECGs, cardiac monitors, Holter systems, blood-pressure monitors, implantable loop recorders, and hospital telemetry are being complemented by wearable medical devices and sensor-based platforms. TGA specifically regulates software-based medical devices and wearables when they are intended for diagnosis, monitoring, prediction, prognosis, or treatment, creating a pathway for clinically oriented smartwatches, biosensors, patches, and digital monitoring systems. Device-generated cardiac information can also contribute to real-world evidence, including information generated by pacemakers, ICDs, and remote heart-rhythm monitors.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Australia Cardiovascular Devices By Application
• Australia’s CAD device segment is characterized by integrated catheter-based diagnosis and intervention, combining coronary angiography, guidewires, balloons, stents, intravascular assessment, and procedural imaging. An important market characteristic is the high regulatory sensitivity associated with devices that directly interact with the heart or central circulatory system: TGA classification rules place certain surgically invasive cardiovascular catheters and long-term vascular implants in high-risk categories. Consequently, coronary-device manufacturers must place particular emphasis on clinical evidence, safety, intended use, and lifecycle compliance rather than treating device registration as a purely administrative step.
• Australia’s heart-failure device segment is increasingly centered on long-term device-enabled management rather than one-time intervention, combining CRT, ICDs, pacemakers, ventricular-support technologies, and physiological monitoring. Implantable cardiac devices can generate information that contributes to real-world evidence and ongoing clinical assessment, while connected monitoring creates opportunities for earlier recognition of changes in patient status. The regulatory environment is particularly relevant because high-risk implanted devices are subject to lifecycle obligations extending from pre-market assessment through continuing safety and performance monitoring.
• The cardiac-arrhythmia segment combines electrical diagnosis, rhythm correction, ablation, implanted-device therapy, and remote surveillance. Pacemakers, ICDs, CRT systems, implantable loop recorders, electrophysiology systems, and ablation technologies address different stages of arrhythmia management. TGA's clinical-evidence guidance specifically identifies pacemakers, ICDs, CRT devices, and implantable loop recorders as active implantable cardiac technologies that may simultaneously provide diagnostic and therapeutic functions. This convergence makes device-generated information, programming, remote monitoring, and long-term device management important parts of the value proposition.
• Australia’s structural-heart segment is characterized by advanced valve replacement and repair supported by sophisticated imaging and catheter-based delivery systems. The device ecosystem includes prosthetic heart valves, transcatheter valve technologies, repair systems, delivery catheters, and imaging platforms used for anatomical assessment and procedural guidance. Prosthetic heart valves are specifically identified by TGA as high-risk medical devices, reinforcing the importance of clinical evidence, conformity assessment, traceability, and post-market surveillance. The segment therefore combines highly specialized intervention with stringent lifecycle requirements for implanted cardiovascular products.
• Other cardiovascular applications encompass vascular intervention, emergency cardiac technologies, mechanical circulatory support, intensive-care monitoring, specialized imaging, congenital cardiovascular procedures, and digitally enabled cardiovascular technologies. The segment is particularly diverse because Australia’s regulatory framework covers physical devices, implants, active devices, software, and wearable technologies when they meet the medical-device definition. The introduction of unique device identification requirements from July 2026 further strengthens traceability across the lifecycle, making identification and post-market surveillance increasingly relevant to cardiovascular products beyond conventional implants.

Australia Cardiovascular Devices By End-User
• Hospitals and cardiac centers remain the principal setting for complex cardiovascular intervention, implantation, electrophysiology, cardiac surgery, intensive monitoring, and advanced imaging. High-risk devices such as pacemakers, prosthetic valves, ICDs, cardiovascular catheters, and other implants require specialized infrastructure and trained multidisciplinary teams. Australia’s regulatory system reinforces the importance of institutional safety and lifecycle management because devices must satisfy pre-market requirements and remain subject to post-market monitoring after inclusion in the ARTG.
• Australia does not exactly replicate the U.S. ASC model; outpatient and day-procedure cardiovascular care is incorporated into hospital-based and broader ambulatory healthcare pathways. The shift toward minimally invasive intervention creates opportunities for selected cardiovascular procedures to use shorter-stay models when clinically appropriate. This favors devices that simplify procedural workflows, reduce tissue trauma, shorten recovery, and support reliable post-procedure observation. However, complex cardiovascular interventions remain strongly dependent on hospitals because of their need for emergency backup, specialist teams, advanced imaging, and intensive-care capabilities.
• Specialty clinics are increasingly important for cardiac diagnostics, electrophysiology, rhythm management, implant follow-up, chronic cardiovascular disease management, and outpatient monitoring. Their role is supported by the growing availability of portable and software-enabled technologies that can collect cardiovascular information outside major hospital environments. TGA’s regulatory framework explicitly encompasses software-based medical devices and wearable technologies intended for clinical monitoring, allowing specialist clinics to incorporate digital cardiac assessment alongside conventional ECG and monitoring equipment.
• Australia’s home-care cardiovascular-device segment is developing around wearable monitoring, remote physiological surveillance, connected implantable devices, and digitally supported chronic-care management. TGA recognizes wearable devices that monitor health-related parameters and may regulate them as medical devices when their intended purpose includes diagnosis, monitoring, prediction, prognosis, or treatment. Device-generated data from implanted and wearable technologies can also support clinical decision-making and real-world evidence, making secure connectivity, patient usability, data quality, and integration with professional oversight increasingly important characteristics of home-oriented cardiovascular technologies.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari


Aspects covered in this report
• Cardiovascular Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Device Type
• Therapeutic and Surgical Devices
• Diagnostic and Monitoring Devices

By Application
• Coronary Artery Disease (CAD)
• Heart Failure
• Cardiac Arrhythmia
• Structural Heart Disease
• Other Applications

By End User
• Hospitals & Cardiac Centers
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Home-Care Settings

Table of Contents

  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Australia Geography
  • 4.1. Population Distribution Table
  • 4.2. Australia Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Key Insights
  • 5.2. Recent Developments
  • 5.3. Market Drivers & Opportunities
  • 5.4. Market Restraints & Challenges
  • 5.5. Market Trends
  • 5.6. Supply chain Analysis
  • 5.7. Policy & Regulatory Framework
  • 5.8. Industry Experts Views
  • 6. Australia Cardiovascular Devices Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast, By Device Type
  • 6.3. Market Size and Forecast, By Application
  • 6.4. Market Size and Forecast, By End User
  • 6.5. Market Size and Forecast, By Region
  • 7. Australia Cardiovascular Devices Market Segmentations
  • 7.1. Australia Cardiovascular Devices Market, By Device Type
  • 7.1.1. Australia Cardiovascular Devices Market Size, By Therapeutic and Surgical Devices, 2020-2031
  • 7.1.2. Australia Cardiovascular Devices Market Size, By Diagnostic and Monitoring Devices, 2020-2031
  • 7.2. Australia Cardiovascular Devices Market, By Application
  • 7.2.1. Australia Cardiovascular Devices Market Size, By Coronary Artery Disease (CAD), 2020-2031
  • 7.2.2. Australia Cardiovascular Devices Market Size, By Heart Failure, 2020-2031
  • 7.2.3. Australia Cardiovascular Devices Market Size, By Cardiac Arrhythmia, 2020-2031
  • 7.2.4. Australia Cardiovascular Devices Market Size, By Structural Heart Disease, 2020-2031
  • 7.2.5. Australia Cardiovascular Devices Market Size, By Other Applications, 2020-2031
  • 7.3. Australia Cardiovascular Devices Market, By End User
  • 7.3.1. Australia Cardiovascular Devices Market Size, By Hospitals & Cardiac Centers, 2020-2031
  • 7.3.2. Australia Cardiovascular Devices Market Size, By Ambulatory Surgical Centers (ASCs), 2020-2031
  • 7.3.3. Australia Cardiovascular Devices Market Size, By Specialty Clinics, 2020-2031
  • 7.3.4. Australia Cardiovascular Devices Market Size, By Home-Care Settings, 2020-2031
  • 7.4. Australia Cardiovascular Devices Market, By Region
  • 7.4.1. Australia Cardiovascular Devices Market Size, By North, 2020-2031
  • 7.4.2. Australia Cardiovascular Devices Market Size, By East, 2020-2031
  • 7.4.3. Australia Cardiovascular Devices Market Size, By West, 2020-2031
  • 7.4.4. Australia Cardiovascular Devices Market Size, By South, 2020-2031
  • 8. Australia Cardiovascular Devices Market Opportunity Assessment
  • 8.1. By Device Type, 2026 to 2031
  • 8.2. By Application, 2026 to 2031
  • 8.3. By End User, 2026 to 2031
  • 8.4. By Region, 2026 to 2031
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.1.1. Company Snapshot
  • 9.2.1.2. Company Overview
  • 9.2.1.3. Financial Highlights
  • 9.2.1.4. Geographic Insights
  • 9.2.1.5. Business Segment & Performance
  • 9.2.1.6. Product Portfolio
  • 9.2.1.7. Key Executives
  • 9.2.1.8. Strategic Moves & Developments
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

Table 1: Influencing Factors for Cardiovascular Devices Market, 2025
Table 2: Australia Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Million)
Table 3: Australia Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Million)
Table 4: Australia Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Million)
Table 5: Australia Cardiovascular Devices Market Size and Forecast, By Region (2020 to 2031F) (In USD Million)
Table 6: Australia Cardiovascular Devices Market Size of Therapeutic and Surgical Devices (2020 to 2031) in USD Million
Table 7: Australia Cardiovascular Devices Market Size of Diagnostic and Monitoring Devices (2020 to 2031) in USD Million
Table 8: Australia Cardiovascular Devices Market Size of Coronary Artery Disease (CAD) (2020 to 2031) in USD Million
Table 9: Australia Cardiovascular Devices Market Size of Heart Failure (2020 to 2031) in USD Million
Table 10: Australia Cardiovascular Devices Market Size of Cardiac Arrhythmia (2020 to 2031) in USD Million
Table 11: Australia Cardiovascular Devices Market Size of Structural Heart Disease (2020 to 2031) in USD Million
Table 12: Australia Cardiovascular Devices Market Size of Other Applications (2020 to 2031) in USD Million
Table 13: Australia Cardiovascular Devices Market Size of Hospitals & Cardiac Centers (2020 to 2031) in USD Million
Table 14: Australia Cardiovascular Devices Market Size of Ambulatory Surgical Centers (ASCs) (2020 to 2031) in USD Million
Table 15: Australia Cardiovascular Devices Market Size of Specialty Clinics (2020 to 2031) in USD Million
Table 16: Australia Cardiovascular Devices Market Size of Home-Care Settings (2020 to 2031) in USD Million
Table 17: Australia Cardiovascular Devices Market Size of North (2020 to 2031) in USD Million
Table 18: Australia Cardiovascular Devices Market Size of East (2020 to 2031) in USD Million
Table 19: Australia Cardiovascular Devices Market Size of West (2020 to 2031) in USD Million
Table 20: Australia Cardiovascular Devices Market Size of South (2020 to 2031) in USD Million

Figure 1: Australia Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Million)
Figure 2: Market Attractiveness Index, By Device Type
Figure 3: Market Attractiveness Index, By Application
Figure 4: Market Attractiveness Index, By End User
Figure 5: Market Attractiveness Index, By Region
Figure 6: Porter's Five Forces of Australia Cardiovascular Devices Market

Australia Cardiovascular Devices Market Research FAQs

Coronary artery disease is a major application because its treatment often involves angiography, angioplasty, stenting, or bypass surgery.

Complex cardiac procedures require catheterization laboratories, specialized surgeons, intensive monitoring, imaging systems, and emergency-care infrastructure.

Rising cardiovascular disease burden, improved specialist care, expanding hospital infrastructure, and greater access to interventional procedures are key factors.

China combines a large patient population with extensive hospital infrastructure and an established network of cardiovascular intervention centers.
Logo

Australia Cardiovascular Devices Market Overview, 2031

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.